



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 47/48, 38/09, 9/10, 9/14, 9/19	A1	(11) International Publication Number: WO 00/47234 (43) International Publication Date: 17 August 2000 (17.08.00)
(21) International Application Number: PCT/EP00/00697 (22) International Filing Date: 29 January 2000 (29.01.00) (30) Priority Data: 60/119,076 8 February 1999 (08.02.99) US (71) Applicant: ASTA MEDICA AKTIENGESELLSCHAFT [DE/DE]; An der Pikardie 10, D-01277 Dresden (DE). (72) Inventors: BAUER, Horst; Röhrenstrasse 12a, D-91217 Hersbruck (DE). DEGER, Wolfgang; Vordere Dauserad 14, D-63755 Alzenau (DE). SARLIKIOTIS, Werner; Sp. Dima 31, GR-190 02 Peania (GR). DAMM, Michael; Dieburger Strasse 106, D-63322 Rödermark (DE).		(81) Designated States: AU, BG, BR, BY, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, YU, ZA, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: SUSTAINED RELEASE SALTS OF PHARMACEUTICALLY ACTIVE PEPTIDES AND THEIR PRODUCTION (57) Abstract Substained delivery pharmaceutical compositions comprise a water insoluble salt of a pharmaceutically active ionic peptide and a counterionic carrier macromolecule. The peptide may be an LHRH antagonist such as cetorelix and the macromolecule may be an anionic polysaccharide such as carboxymethylcellulose. The salt is prepared using ion exchangers to sepArately remove the counterions from the peptide and the carrier macromolecule thereby forming free peptide/macromolecule ions. These free peptide and macromolecule ions are then combined to form the water insoluble peptide-macromolecule salt.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SUSTAINED RELEASE SALTS OF PHARMACEUTICALLY ACTIVE PEPTIDES AND THEIR PRODUCTION

Background of the Invention

5

Field of Invention

10 This invention relates to pharmaceutical compositions of pharmacologically-active polypeptides, which provide sustained release of the polypeptide over an extended period of time.

Description of the Prior Art

15 According to the prior art (WO 98/25642) pharmaceutical formulations are claimed comprising a stable water-insoluble complex composed of a peptidic compound (e.g., a peptide, polypeptide, protein, peptidomimetic and the like), preferably a pharmaceutically active peptidic compound, and a carrier macromolecule that allow for sustained delivery of the peptidic compound in vivo upon administration of the complex. The complex according to the prior art can permit continuous delivery of a
20 pharmaceutically active peptidic compound to a subject for prolonged periods of time, e.g., one month. Moreover, the association of the peptidic compound and the carrier macromolecule in a tight, stable complex allows for loading of high concentrations of the peptidic compound into the formulation.

25 The complex of the invention according to the prior art is formed by combining the peptidic compound and the carrier macromolecule under conditions such that a substantially water-insoluble complex is formed, e.g, aqueous solutions of the peptidic compound and carrier macromolecule are mixed until the complex precipitates.

30

The complex may be in the form of a solid (e.g., a paste, granules, a powder or a lyophilizate) or the powdered form of the complex can be pulverized finely enough to form stable liquid suspensions or semi-solid dispersions.

In a preferred embodiment, the peptidic compound of the water-insoluble complex is an LHRH analogue, more preferably an LHRH antagonist, and the carrier macromolecule is an anionic polymer, preferably sodium carboxymethylcellulose.

The complex of the invention is suitable for sterilization, such as by gamma

5 irradiation or electron beam irradiation, prior to administration in vivo.

Methods for treating a subject for a condition treatable with an LHRH analogue by administering to the subject an LHRH-analogue-containing composition of the invention are also provided.

10

Problems presented by the Prior Art

For manufacturing the claimed complexes rather highly concentrated solutions (5 - 25 mg/ml) of the peptidic compound in water have to be prepared. Because of the

15 inherent tendency of many peptidic compounds to aggregate, it can not be ensured that aggregate-free solutions in pure water can be prepared using the claimed manufacturing procedure. Depending on the water solubility of a specific peptidic compound and on the technique used to prepare this solution, the concentrated peptide solution in water may be aggregate-free or contaminated with varying

20 concentrations and different types of peptidic aggregates and precipitates. As this highly concentrated peptidic solution is the starting material for the production of the claimed complexes, the dissolution of the peptidic compound in water is obviously a critical step.

25 By adding an aqueous solution of sodium carboxymethylcellulose to this not well defined and characterized, highly concentrated peptide solutions in varying ratios (0,1:1 to 0,5: 1 w/w) complexes or precipitates are formed spontaneously in a non-defined, uncontrolled manner. The precipitates are collected by filtration or centrifugation, washed by rinsing with water and dried. The solid material is then

30 powdered using a mortar and pestle. Afterwards the content of the peptidic compound is analytically determined. Due to the manufacturing procedure, the formation of stoichiometric complexes in a reproducible and well defined manner can not be guaranteed.

Additionally, by adding a solution of sodium carboxymethylcellulose (containing 6,5-9,5 % sodium according to USP) a significant amount of metall ions, i.e. sodium ions, comes into contact with the peptidic compound. Peptides and proteins might be precipitated in the presence of salts. Therefore, it is not clear, whether the complexes or precipitates described in the prior art are formed because of interactions between the peptidic compound and the functional groups of carboxymethylcellulose itself or solely by the peptide precipitating effect of the sodium ions or by unknown and non-controllable mixtures of these two processes.

After drying and milling the peptide formulations described in the prior art are suspended in saline, which also can lead to further undesirable, uncontrolled interaction processes.

Summary of the Invention

The present invention provides pharmaceutical compositions comprising a stable, well defined, stoichiometric salt composed of an acidic or basic peptidic compound (like peptide, polypeptide protein, peptidominetic etc.) and of an ionic, basic or acidic, carrier macromolecule, respectively, allowing sustained delivery of the peptidic compound after in vivo administration of the salt of a specific peptidic compound.

The ionic carrier macromolecule may be an anionic polymer, for example an anionic polyalcohol, a derivative or a fragment thereof.

Furthermore the ionic carrier macromolecule can be an anionic polysaccharide, a derivative or a fragment thereof. Preferably the carrier macromolecule is carboxymethylcellulose. The carrier macromolecule in the pharmaceutical composition can further be selected from the group consisting of algin, alginic acid, sodium alginate, anionic acetate polymers, ionic acrylic or methacrylic polymers and copolymers, pectin, tragacanth, xanthan gums, anionic carageenan derivatives,

anionic polygalacturonic acid derivatives, sulfated and sulfonated polystyrene, sodium starch glycolate, and fragments or derivatives thereof.

5 The ionic carrier macromolecule can also be albumin, gelatin (type A or type B), and a fragment or derivative thereof.

Cationic polymers can also be poly-L-lysine and other polymers of basic amino acids.

10 The peptide in the compound is a pharmaceutically active peptidic compound and can be a mono-, di- or multivalent cationic or anionic polypeptide, wherein the polypeptide is 5 to 100 amino acids in length, preferably 5 to 20 amino acids in length, more preferably the peptide is 8 to 12 amino acids in length. More in detail the peptidic compound is an LHRH analogue and the LHRH analogue is an LHRH antagonist. The LHRH analogue is for example Cetrorelix, Teverelix (Antarelix, 15 Deghenghi et al., Biomed & Pharmacother 1993, 47, 107), Abarelix (Molineaux et al., Molecular Urology 1998, 2, 265), Ganirelix (Nestor et al., J. Med. Chem. 1992, 35, 3942), Azaline B, Antide, A-75998 (Cannon et al., J. Pharm. Sci. 1995, 84, 953), Detirelix (Andreyko et al., J. Clin. Endocrinol. Metab. 1992, 74, 399), RS-68439, Ramorelix (Stoeckemann and Sandow, J. Cancer Res. Clin. Oncol. 1993, 119, 457), 20 Nal-Glu. Structures of the above mentioned LHRH analogues are provided for example in the above cited references and in following reviews: Behre et al., GnRH antagonists: an overview, Proceedings of the 2nd World Conference on Ovulation Induction, The Parthenon Publishing Group Ltd, UK; Kutscher et al., Angew. Chem. 1997, 109, 2240.

25

Moreover a method of preparation of such salts is described.

30 According to the invention, the free base or the free acid of the peptidic compound is prepared by removing the counter ion using ion exchangers. Also, the free base or the free acid of the carrier macromolecule is prepared by removing the counter ion using ion exchangers. Thereupon, equivalent amounts of the freshly prepared peptide base or peptide acid solution, respectively, and of the counterionic-free macromolecule carrier solution are combined. The ratio of peptidic compound to

carrier macromolecule (w/w) can be, for example, 1:0.1, 1:0.213, 1:0.5, 1:2.13. Non-limiting examples of conditions and procedures for preparing a water-insoluble complex of the invention are described in Examples 1 to 4.

- 5 This process results in well defined, stoichiometric and pure salts of the peptidic compound with a counterionic macromolecule. These pure salts are not contaminated by other ions, neither anions (e.g. acetate) nor cations (e.g. sodium).

10 The pharmaceutical compositions of the invention permit sustained delivery of the peptidic compound to a subject in vivo after administration of the composition to the subject. The duration and the extent of the sustained delivery can be varied depending upon the concentration of the peptidic compound and the carrier macromolecule used to form the salt.

15

Example 1

A lyophilisate of cetorelix-CMC-salt with a mass ratio cetorelix : CMC of 1:0.1 resembling a molar ratio cetorelix : carboxylic function of CMC of 1:0.48 was
20 prepared as follows. 0.22 g Na-CMC (low viscosity grade carboxymethylcellulose, Hercules) was dissolved in 40 g water and 3 g ion exchanger (Amberlite[®]) was added. After stirring for 20 min the ion exchanger was removed by filtration using a glas fibre filter. 2.21 g cetorelix acetate was dissolved in 23.4 g water and 74.6 g ethanol 96 % (v/v) was added. 20 g ion exchanger (Amberlite[®]) was added. After
25 stirring for 20 min the ion exchanger was removed by filtration using a glas fibre filter. The filtrated cetorelix base solution was added under continuous stirring to the sodium-free CMC-solution yielding a clear solution. After 1 hour stirring the solution was evaporated under vacuum to remove the ethanol yielding a dispersion. Finally, the dispersion was frozen and freeze-dried.

30

Example 2

A lyophilisate of cetorelix-CMC-salt with a mass ratio cetorelix : CMC of 1:0.213 resembling a molar ratio cetorelix : carboxylic function of CMC of 1:1 was prepared as follows. 0.426 g Na-CMC (low viscosity grade carboxymethylcellulose, Hercules) was dissolved in 40 g water and 5 g ion exchanger (Amberlite[®]) was added. After stirring for 25 min the ion exchanger was removed by filtration using a glas fibre filter. 2.21 g cetorelix acetate was dissolved in 23.4 g water and 74.6 g ethanol 96 % (v/v) was added. 20 g ion exchanger (Amberlite[®]) was added. After stirring for 20 min the ion exchanger was removed by filtration using a glas fibre filter. The filtrated cetorelix base solution was added under continuous stirring to the sodium-free CMC-solution yielding a clear solution. After 1 hour stirring the solution was evaporated under vacuum to remove the ethanol yielding a dispersion. Finally, the dispersion was frozen and freeze-dried.

15 Example 3

A lyophilisate of cetorelix-CMC-salt with a mass ratio cetorelix : CMC of 1:0.5 resembling a molar ratio cetorelix : carboxylic function of CMC of 1:2.41 was prepared as follows. 1.1 g Na-CMC (low viscosity grade carboxymethylcellulose, Hercules) was dissolved in 200 g water and 15 g ion exchanger (Amberlite[®]) was added. After stirring for 20 min the ion exchanger was removed by filtration using a glas fibre filter. 2.21 g cetorelix acetate was dissolved in 23.4 g water and 74.6 g ethanol 96 % (v/v) was added. 20 g ion exchanger (Amberlite[®]) was added. After stirring for 20 min the ion exchanger was removed by filtration using a glas fibre filter. The filtrated cetorelix base solution was added under continuous stirring to the sodium-free CMC-solution yielding a solution. After 1 hour stirring the solution was evaporated under vacuum to remove the ethanol yielding a dispersion. Finally, the dispersion was frozen and freeze-dried.

30 Example 4

A lyophilisate of cetorelix-CMC-salt with a mass ratio cetorelix : CMC of 1:2.13 resembling a molar ratio cetorelix : carboxylic function of CMC of 1:10 was prepared as follows. 4.26 g Na-CMC (low viscosity grade carboxymethylcellulose, Hercules) was dissolved in 400 g water and 50 g ion exchanger (Amberlite®) was added. After stirring for 25 min the ion exchanger was removed by filtration using a glas fibre filter. 2.21 g cetorelix acetate was dissolved in 23.4 g water and 74.6 g ethanol 96 % (v/v) was added. 20 g ion exchanger (Amberlite®) was added. After stirring for 20 min the ion exchanger was removed by filtration using a glas fibre filter. The filtrated cetorelix base solution was added under continuous stirring to the sodium-free CMC-solution yielding a turbid dispersion. After 1 hour stirring the dispersion was evaporated under vacuum to remove the ethanol. Finally, the dispersion was frozen and freeze-dried.

Example 5

The solubility of sodium-free, pure CMC-salts with varying compositions peptide-base : CMC acid was determined in isotonic Ringer solution. The cetorelix-CMC-salts were prepared according to example 1 to 4. Additionally, the in vitro release in Ringer solution of cetorelix out of these sodium-free CMC-salts was tested over a time period of 168 hours using a flow-through-system. The amount of cetorelix released after 168 h is expressed as percentage of the cetorelix dose applied in this in vitro test method.

peptide-base:CMC (w/w)	solubility in Ringer solution in µg/ml	in vitro release in Ringer solution after 168 h in %
1:0,1	3,5	23
1:0,213	2,7	30
1:0,5	17,5	63
1:2,13	54	76

These in vitro data of the sodium-free CMC-salts according to this invention were compared with cetorelix complexes manufactured with Na-CMC in identical mass ratios of peptide and CMC according to the prior art (WO 98/25642).

peptide-base:Na-CMC (m/m)	solubility in Ringer solution in µg/ml	in vitro release in Ringer solution after 168 h in %
1:0,1	2,5	46
1:0,253	1,5	48
1:0,5	2	45
1:2,13	2	17

The elimination of sodium and acetate ions in the peptide CMC-salts is leading to significant improvements in the in vitro behaviour of such formulations, i.e. solubility and in vitro release characteristics.

In the Na-CMC complexes according to the prior art the solubility in Ringer solution is very low and can not be modified by changing the ratio of the components peptide and Na-CMC. Thus, the release kinetics of the peptidic compound out of these formulations cannot be modified.

In contrast, within the sodium-free CMC-salts of the peptidic compound prepared according to the invention there is a clear dependence between the mass ratio of the salt components and their in vitro behaviour. An increase in the percentage of sodium-free CMC acid within such formulations leads to a significant increase in the solubility of the peptidic compound in Ringer solution. Thus, the release kinetics of the peptidic compound out of these sodium-free CMC-salt formulations can be modified and controlled. Therefore, depending on the desired release kinetics for certain clinical applications, definite CMC-salt formulations with appropriate release patterns can be made available.

Example 6

Both sodium-free CMC-salts of cetorelix according to Examples 1 to 4 and Na-CMC-complexes of cetorelix with equivalent mass ratios cetorelix : CMC according to the prior art were prepared. Suspensions of such sodium-free CMC-salts of cetorelix

and of Na-CMC-complexes of cetorelix, respectively, were prepared and a single dose was injected intramuscularly into rats in a dosage of 1,5 mg/kg. Plasma testosterone levels and plasma cetorelix levels were determined at various time points. Additionally, at the end of the testosterone suppression the rats were killed.

- 5 The muscle, into which the dose was injected, was removed and analyzed for the residual of the administered cetorelix dose at the injection site.

Results are shown in Figure 1.

The absolute bioavailability of the Cetorelix-CMC salts was in the range of 78%-111%. The bioavailability of the Cetorelix-Na-CMC complexes was only 32%

- 10 indicating the negative influence of the sodium ions on the properties of the formulations prepared according to the prior art.

Example 7

15

Sodium-free CMC-salts of cetorelix according to this invention as described in previous examples were prepared as lyophilisates. The lyophilisates were dispersed in aqueous media and a single dose was injected subcutaneously into dogs in a dosage of 1,0 mg/kg. Plasma testosterone levels and plasma cetorelix levels were

20 determined at various time points. Results are shown in Figure 2.

Claims

1. A pharmaceutical composition comprising a water-insoluble salt of a
pharmaceutically active ionic peptidic compound and a counterionic carrier
5 macromolecule.
2. The pharmaceutical composition of claim 1, wherein the pharmaceutically active
peptidic compound is cationic and the carrier macromolecule is anionic.
- 10 3. The pharmaceutical composition of claim 1, wherein the pharmaceutically active
peptidic compound is anionic and the carrier macromolecule is cationic.
4. The pharmaceutical composition of claim 1, wherein the formation of the water-
insoluble salt can be mediated additionally at least in part by hydrogen bonding
15 between the pharmaceutically active peptidic compound and the carrier
macromolecule.
5. The pharmaceutical composition of claim 1, wherein the formation of the water-
insoluble salt can be mediated additionally at least in part by hydrophobic
20 interactions between the pharmaceutically active peptidic compound and the
carrier macromolecule.
6. The pharmaceutical composition of claim 1, wherein a single dose of the water-
insoluble salt provides sustained delivery of the pharmaceutically active peptide to
25 a subject for at least one week after the pharmaceutical composition is
administrated to the subject.
7. The pharmaceutical composition of claim 1, wherein a single dose of the water-
insoluble salt provides sustained delivery of the pharmaceutically active peptide to
30 a subject for at least two weeks after the pharmaceutical composition is
administrated to the subject.

8. The pharmaceutical composition of claim 1, wherein a single dose of the water-insoluble salt provides sustained delivery of the pharmaceutically active peptide to a subject for at least three weeks after the pharmaceutical composition is administered to the subject.

5

9. The pharmaceutical composition of claim 1, wherein a single dose of the water-insoluble salt provides sustained delivery of the pharmaceutically active peptide to a subject for at least four weeks after the pharmaceutical composition is administered to the subject.

10

10. The pharmaceutical composition of claim 1, wherein the pharmaceutically active peptidic compound is a mono-, di- or multivalent cationic or anionic peptide.

15

11. The pharmaceutical composition of claim 1, wherein the peptidic compound is a mono-, di- or multivalent ampholytic peptide.

12. The pharmaceutical composition of claim 1, wherein the peptide is 5 to 100 amino acids in length.

20

13. The pharmaceutical composition of claim 1, wherein the peptide is 5 to 20 amino acids in length.

14. The pharmaceutical composition of claim 1, wherein the peptide is 8 to 12 amino acids in length.

25

15. The pharmaceutical composition of claim 1, wherein the carrier macromolecule is an anionic polymer.

30

16. The pharmaceutical composition of claim 1, wherein the carrier macromolecule is an ampholytic polymer.

17. The pharmaceutical composition of claim 1, wherein the carrier macromolecule is an anionic polyalcohol, a derivative or a fragment thereof.

18. The pharmaceutical composition of claim 1, wherein the carrier macromolecule is an anionic polysaccharide, a derivative or a fragment thereof, or a pharmaceutically acceptable salt thereof.

5

19. The pharmaceutical composition of claim 1, wherein the carrier macromolecule is carboxymethylcellulose.

20. The pharmaceutical composition of claim 1, wherein the carrier macromolecule is selected from the group consisting of algin, alginic acid, sodium alginate, anionic acetate polymers, ionic acrylic or methacrylic polymers and copolymers, pectin, tragacanth, xanthan gums, anionic carageenan derivatives, anionic polygalacturonic acid derivatives, sulfated and sulfonated polystyrene, sodium starch glycolate, and fragments or derivatives thereof, respectively.

15

21. The pharmaceutical composition of claim 1, wherein the ionic carrier macromolecule is selected from the group consisting of albumins, gelatin type A, gelatin type B, and fragments or derivatives thereof.

22. The pharmaceutical composition of claim 1, wherein the ionic carrier is a cationic macromolecule like poly-L-lysine and other polymers of basic amino acids

23. The pharmaceutical composition of claim 1, which is a dry solid.

24. The pharmaceutical composition of claim 1, which is a liquid suspension or semi-solid dispersion.

25. A pharmaceutical composition comprising a water-insoluble salt, wherein the water-insoluble salt consists essentially of a pharmaceutically active peptidic compound and a carrier macromolecule.

30

26. The pharmaceutical composition of claim 25 comprising a water-insoluble salt of an LHRH analogue and a carrier macromolecule.

27. The pharmaceutical composition of claim 26 comprising a water-insoluble salt of an LHRH antagonist and a carrier macromolecule.

5 28. The pharmaceutical composition of claim 25, wherein the peptide-CMC-salt has a mass ratio peptide : CMC ranging from 1:0.006 to 1:40, preferably from 1:0.04 to 1:14, more preferably from 1:0.1 to 1:5, especially from 1:0.1 to 1:3.

10 29. The pharmaceutical composition of claim 26, wherein the peptide-CMC-salt has a mass ratio peptide : CMC ranging from 1:0.006 to 1:40, preferably from 1:0.04 to 1:14, more preferably from 1:0.1 to 1:5, especially from 1:0.1 to 1:3.

15 30. The pharmaceutical composition of claim 27, wherein the peptide-CMC-salt has a mass ratio peptide : CMC ranging from 1:0.006 to 1:40, preferably from 1:0.04 to 1:14, more preferably from 1:0.1 to 1:5, especially from 1:0.1 to 1:3.

31. The pharmaceutical composition of claim 27, wherein the LHRH antagonist is cetorelix.

20 32. The pharmaceutical composition of claim 30, wherein the peptide is cetorelix.

33. The pharmaceutical composition of claim 30, wherein the peptide salt is a cetorelix-CMC-salt with a mass ratio cetorelix : CMC of 1:0.1.

25 34. The pharmaceutical composition of claim 30, wherein the peptide salt is a cetorelix-CMC-salt with a mass ratio cetorelix : CMC of 1:0.213.

35. The pharmaceutical composition of claim 30, wherein the peptide salt is a cetorelix-CMC-salt with a mass ratio cetorelix : CMC of 1:0.5.

30 36. The pharmaceutical composition of claim 30, wherein the peptide salt is a cetorelix-CMC-salt with a mass ratio cetorelix : CMC of 1:2.13.

37. A method for preparing a pharmaceutical formulation, comprising a peptidic compound and a carrier macromolecule; forming the free ions of both compounds by removing the counter ions; combining the ionic peptidic compound and the ionic carrier macromolecule under conditions such that a water-insoluble salt of the peptidic compound and the carrier macromolecule forms; and preparing a pharmaceutical formulation comprising the water insoluble salt.

38. The method of claim 37 wherein a solution of the ionic peptidic compound and a solution of the carrier macromolecule are fresh prepared before combined to form a water-insoluble salt of the peptidic compound and the carrier macromolecule.

39. The method of claim 37 wherein a solution of the ionic peptidic compound and a solution of the carrier macromolecule are combined to form a water-insoluble salt of the peptidic compound and the carrier macromolecule.

40. The method of claim 37, further comprising sterilizing the water-insoluble salt by gamma irradiation or electron beam irradiation.

41. The method of claim 37, wherein the water-insoluble salt is formed using aseptic procedures.

42. The method of claim 37, wherein the peptidic compound is cationic and the carrier macromolecule is anionic.

43. The method of claim 37, wherein the peptidic compound is anionic and the carrier macromolecule is cationic.

44. The method of claim 37, wherein the peptidic compound is a mono-, di- or multivalent cationic or anionic peptide.

45. The method of claim 37, wherein the peptidic compound is a mono-, di- or multivalent ampholytic peptide.

46. The method of claim 37, wherein the peptidic compound is an LHRH analogue.

47. The method of claim 46, wherein the LHRH analogue is an LHRH antagonist.

5 48. The method of claim 47, wherein the LHRH antagonist is Cetrorelix.

49. The method of claim 47, wherein the LHRH antagonist is Teverelix.

50. The method of claim 47, wherein the LHRH antagonist is Abarelix.

10

51. The method of claim 47, wherein the LHRH antagonist is Ganirelix RS-26306.

52. The method of claim 47, wherein the LHRH antagonist is Azaline B.

15 53. The method of claim 47, wherein the LHRH antagonist is Antide ORF-23541.

54. The method of claim 47, wherein the LHRH antagonist is A-75998.

55. The method of claim 47, wherein the LHRH antagonist is Detirelix RS-68439.

20

56. The method of claim 47, wherein the LHRH antagonist is Ramorelix HOE-2013.

57. The method of claim 47, wherein the LHRH antagonist is Nal-Glu ORF-21234.



Figure 1 / Example 6

Figure 2 / Example 7



INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/00697

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K47/48 A61K38/09 A61K9/10 A61K9/14 A61K9/19		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 24150 A (ZENECA LTD) 9 December 1993 (1993-12-09) abstract examples 1-25 ---	1-36
X	US 4 581 169 A (NESTOR JOHN J ET AL) 8 April 1986 (1986-04-08) column 2, line 28 - line 41 column 9, line 17 - line 29 ---	1-36
X	WO 98 32423 A (KAMEI SHIGERU ;SAIKAWA AKIRA (JP); IGARI YASUTAKA (JP); OHTA TSUTO) 30 July 1998 (1998-07-30) page 14, line 18 - line 24 page 15, line 25 - line 34 page 38, line 34 -page 39, line 4 examples 1-15 ---	1-24
-/-		
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents :</p> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*A* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">13 June 2000</div>		Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">10/07/2000</div>
Name and mailing address of the ISA European Patent Office, P.B. 5618 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center; font-weight: bold;">Pilling, S</div>

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/00697

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 25642 A (MOLINEAUX CHRISTOPHER J ;PRAECIS PHARM INC (US); BARKER NICHOLAS () 18 June 1998 (1998-06-18) cited in the application page 1, line 27 -page 2, line 12 page 5, line 26 - line 30 page 6, line 3 - line 10 the examples particularly Examples 9 and 10	1-36
X	WO 98 42381 A (ASTA MEDICA AG) 1 October 1998 (1998-10-01) page 2, line 5 -page 2, line 26 page 3, line 8 - line 9 examples 1-5	1-36
A	US 5 773 032 A (KLOKKERS-BETHKE KARIN ET AL) 30 June 1998 (1998-06-30) the whole document	1-57

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/00697

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9324150 A	09-12-1993	AU 682310 B	02-10-1997
		AU 4084793 A	30-12-1993
		BE 1006143 A	24-05-1994
		CA 2136751 A	09-12-1993
		CH 688911 A	29-05-1998
		CZ 9402937 A	15-03-1995
		DE 4392401 T	24-07-1997
		DK 135394 A	28-11-1994
		ES 2107357 A	16-11-1997
		FI 945553 A	25-01-1995
		FR 2691631 A	03-12-1993
		GB 2282066 A, B	29-03-1995
		GR 1001550 B	29-04-1994
		HK 133097 A	24-10-1997
		HU 70177 A	28-09-1995
		IE 74715 B	30-07-1997
		IT MI931099 A, B	28-12-1993
		JP 8501064 T	06-02-1996
		LU 88559 A	05-04-1995
		MC 2330 A	31-05-1994
		NL 9320034 T	03-04-1995
		NO 944535 A	25-01-1995
		NZ 252268 A	20-12-1996
		SE 501970 C	03-07-1995
		SE 9404115 A	28-11-1994
		SG 44645 A	19-12-1997
		SK 143494 A	11-07-1995
		US 5889110 A	30-03-1999
		ZA 9303358 A	15-09-1994
US 4581169 A	08-04-1986	US 4481190 A	06-11-1984
		AT 37376 T	15-10-1988
		AU 569036 B	21-01-1988
		AU 1567483 A	15-12-1983
		AU 613878 B	15-08-1991
		AU 7941887 A	21-01-1988
		CA 1264760 C	23-01-1990
		CA 1264760 A	23-01-1990
		DE 3378053 D	27-10-1988
		DK 171483 B	25-11-1996
		EP 0097031 A	28-12-1983
		ES 523128 D	16-04-1985
		ES 8504110 A	01-07-1985
		ES 537653 D	16-12-1985
		ES 8603194 A	01-04-1986
		FI 832053 A	11-12-1983
		FI 840116 A	13-01-1984
		IE 55164 B	20-06-1990
		IL 68938 A	31-08-1986
		IL 78380 A	31-08-1986
		JP 1888576 C	07-12-1994
		JP 6010184 B	09-02-1994
		JP 59062556 A	10-04-1984
		KR 9102550 B	24-04-1991
		NO 832098 A	12-12-1983
		NO 834404 A	12-12-1983
		NZ 220763 A	28-06-1989
		US 4667014 A	19-05-1987

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/00697

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4581169 A		HU 199391 B	28-02-1990
		HU 195234 B	28-04-1988
		US 4698442 A	06-10-1987
WO 9832423 A	30-07-1998	AU 5678398 A	18-08-1998
		JP 10273447 A	13-10-1998
WO 9825642 A	18-06-1998	US 5968895 A	19-10-1999
		AU 5699198 A	03-07-1998
		CN 1245436 A	23-02-2000
		CZ 9902066 A	17-11-1999
		EP 0952843 A	03-11-1999
		HR 970674 A	31-08-1998
		PL 334076 A	31-01-2000
		ZA 9710994 A	10-07-1998
WO 9842381 A	01-10-1998	DE 19712718 A	01-10-1998
		AU 6920798 A	20-10-1998
		BR 9807887 A	22-02-2000
		EP 0981377 A	01-03-2000
		NO 994665 A	24-09-1999
		US 6022860 A	08-02-2000
		US 6054555 A	25-04-2000
US 5773032 A	30-06-1998	DE 4342092 A	14-06-1995
		AU 677748 B	01-05-1997
		AU 1219995 A	27-06-1995
		BR 9408272 A	17-12-1996
		CA 2178592 A	15-06-1995
		CN 1136779 A	27-11-1996
		CZ 9601420 A	11-12-1996
		WO 9515767 A	15-06-1995
		EP 0732934 A	25-09-1996
		FI 962354 A	06-06-1996
		HR 940978 A	28-02-1997
		HU 75712 A, B	28-05-1997
		JP 9509145 T	16-09-1997
		LV 11596 A	20-12-1996
		LV 11596 B	20-06-1997
		NO 961877 A	09-05-1996
		NZ 277239 A	24-03-1997
		PL 314913 A	30-09-1996
		SK 66796 A	06-08-1997
		ZA 9409798 A	18-08-1995